Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amrutanjan Health Care Limited reported audited standalone financial results for Q4 and year ended March 31, 2026. Revenue from operations grew 11.23% year-on-year to ₹50,255.27 lakhs (FY26) from ₹45,181.63 lakhs (FY25). Profit after tax increased 13.93% to ₹5,791.78 lakhs from ₹5,083.47 lakhs. Basic and diluted EPS stood at ₹20.03 per share versus ₹17.58 in the prior year. The Board recommended a final dividend of ₹2.90 per share (face value ₹1). Exceptional items of ₹885.67 lakhs included a ₹760.50 lakhs provision for retrospective lease rent revision (Tamil Nadu government matter) and ₹125.17 lakhs impact from new labour codes. The auditor issued an unmodified (clean) opinion. The Board also approved appointment of a new Independent Director, re-appointment of another, and rolling out of a revised ESOP 2 scheme.
The company delivered double-digit revenue and profit growth with strong cash generation from operations at ₹3,596.77 lakhs. The clean audit and dividend declaration are positives. However, the one-time exceptional charges (₹885.67 lakhs) are a one-time hit to profitability that investors should note. The stock could see a modest positive reaction given steady operational performance.